Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Author(s) -
Lawrence Corey,
Peter B. Gilbert,
Michal Juraska,
David C. Montefiori,
Lynn Morris,
Shelly Karuna,
Srilatha Edupuganti,
Nyaradzo Mgodi,
Allan C. deCamp,
Erika Rudnicki,
Yunda Huang,
Pedro Gonzáles,
Robinson Cabello,
Catherine Orrell,
Javier R. Lama,
Fatima Laher,
Erica Lazarus,
Jorge Sánchez,
Ian Frank,
Juan Hinojosa,
Magdalena E. Sobieszczyk,
Kyle Marshall,
Pamela Mukwekwerere,
Joseph Makhema,
Lindsey R. Baden,
James I. Mullins,
Carolyn Williamson,
John Hural,
M. Juliana McElrath,
Carter Bentley,
Simbarashe Takuva,
Margarita M. Gomez Lorenzo,
David Burns,
Nicole Espy,
April Randhawa,
Nidhi Kochar,
Estelle PiwowarManning,
Deborah Donnell,
Nirupama Sista,
P. Andrew,
James G. Kublin,
Glenda Gray,
Julie E. Ledgerwood,
John R. Mascola,
Myron S. Cohen
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2031738
Subject(s) - human immunodeficiency virus (hiv) , antibody , virology , neutralizing antibody , virus , immunology , medicine
Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom